Intravenous iron in heart failure: still no prognostic impact, but questions remain

Intravenous iron in heart failure: still no prognostic impact, but questions remain

Saved in:

Bibliographic Details
Main Authors:	Ibrahim El-Battrawy, Nazha Hamdani, Mohammad Abumayyaleh, Ibrahim Akin
Format:	Article
Language:	English
Published:	Elsevier 2025-08-01
Series:	International Journal of Cardiology: Heart & Vasculature
Subjects:	HFpEF HFrEF Iron deficiency IV iron Inflammation
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352906725001496
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The use of sacubitril/valsartan in different forms of heart failure
by: Mohammad Abumayyaleh, et al.
Published: (2025-06-01)

Hospitalized patients and stimulant use-associated heart failure: importance of ejection fraction and related risk factors
by: Akshat Agrawal, et al.
Published: (2025-07-01)

Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia
by: Kengo Ayabe, et al.
Published: (2024-10-01)

Small Heart Size and Premature Death in 366,484 Individuals With Normal Ejection Fraction
by: Stephanie J. Rowe, BBiomed, MD, et al.
Published: (2025-01-01)

Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis
by: Wanqian Yu, et al.
Published: (2025-05-01)

Phenotyping patients with chronic obstructive pulmonary disease and heart failure
by: Peter Moritz Becher, et al.
Published: (2025-04-01)

Correction: Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis
by: Wanqian Yu, et al.
Published: (2025-07-01)

EVOLUTION‐HF DEallEF: A non‐interventional study of patients with heart failure initiated on dapagliflozin: study design
by: Matthias Paul, et al.
Published: (2025-08-01)

Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First‐in‐Human, Randomized, Single‐Blind, Placebo‐Controlled Study
by: Kathleen Connolly, et al.
Published: (2024-08-01)

Multi‐microRNA diagnostic panel for heart failure with preserved ejection fraction in preclinical and clinical settings
by: Reza Parvan, et al.
Published: (2025-08-01)

Real‐world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction
by: Jenni Huusko, et al.
Published: (2020-06-01)

Atrial Fibrillation, Heart Failure Phenotypes, and Mortality Risk in the Nationwide START Registry: A Propensity Score Matching Analysis
by: Danilo Menichelli, et al.
Published: (2025-06-01)

Prognostic and predictive microRNA panels for heart failure patients with reduced or preserved ejection fraction: a meta-analysis of Kaplan–Meier-based individual patient data
by: Reza Parvan, et al.
Published: (2025-07-01)

The Efficacy and Safety of Ferric Carboxymaltose in Heart Failure with Reduced Ejection Fraction and Iron Deficiency: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Inderbir Padda, et al.
Published: (2024-12-01)

Incidence of atrial fibrillation in patients with an insertable cardiac monitor and symptomatic heart failure
by: Muhammad Shahzeb Khan, et al.
Published: (2025-06-01)

Changes in Cardiac Function and Exercise Capacity Following Ferric Carboxymaltose Administration in HFrEF Patients with Iron Deficiency
by: Anastasios Tsarouchas, et al.
Published: (2025-08-01)

Impact of severe obesity on exercise performance in heart failure with preserved ejection fraction
by: Satyam Sarma, et al.
Published: (2020-11-01)

Clinical profile of heart failure in geriatric patients in a tertiary cardiac hospital of Bangladesh
by: Mahbuba Yesmin, et al.
Published: (2025-06-01)

Machine Learning-Driven Prediction of One-Year Readmission in HFrEF Patients: The Key Role of Inflammation
by: Ma F, et al.
Published: (2025-07-01)

The Role of Inflammation in the Pathophysiology of Heart Failure
by: Marwan Amara, et al.
Published: (2025-07-01)

Cardiometabolic heart failure with preserved ejection fraction: from molecular signatures to personalized treatment
by: Era Gorica, et al.
Published: (2025-07-01)

Impact of Voluntary Exercise on Systemic Inflammation in a 2‐Hit Model of Heart Failure With Preserved Ejection Fraction
by: Heather Quiriarte, et al.
Published: (2025-02-01)

Cardiopulmonary exercise testing as a prognosis‐assessing tool in heart failure with preserved ejection fraction
by: C. Rozados daConceicao, et al.
Published: (2025-06-01)

Exploring the Noninvasive Evaluation of the Pulmonary Pressure–Flow Relationship During Exercise
by: Mads J. Andersen, et al.
Published: (2024-08-01)

The Possible Role of Rosuvastatin Therapy in HFpEF Patients—A Preliminary Report
by: Tomasz Urbanowicz, et al.
Published: (2024-11-01)

Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide
by: Zsombor I. Hegedűs, et al.
Published: (2025-06-01)

Cough as the first symptom of chronic heart failure: A case report of a 72-year-old woman
by: Paulina Sroczyńska, et al.
Published: (2025-02-01)

A higher mortality in men compared to women with heart failure in primary care and ejection fraction equal to or more than 40%
by: Björn Eriksson, et al.
Published: (2024-12-01)

Hypocalcaemic cardiomyopathy presenting as heart failure exacerbation due to untreated primary hypoparathyroidism
by: Massimo Mapelli, et al.
Published: (2025-02-01)

The Quality of Life in Heart Failure Reduced Ejection Fraction (HFrEF) Patients: A Phenomenon of Obesity Paradox
by: Yogi Puji Rachmawan, et al.
Published: (2025-01-01)

Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
by: Mark Sweeney, et al.
Published: (2020-09-01)

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction
by: Shuo Xu, et al.
Published: (2025-04-01)

Multiparity induces persistent myocardial structural, functional and transcriptomic remodelling in mice
by: Ruth R. Magaye, et al.
Published: (2025-07-01)

Carbohydrate antigen-125 (CA125): a marker of right ventricular dysfunction and poor prognosis in heart failure with preserved ejection fraction
by: Sher May Ng, et al.
Published: (2025-10-01)

Association of Kidney Function With Incident Heart Failure: An Analysis of the Women's Health Initiative
by: Richard K. Cheng, et al.
Published: (2025-03-01)

Echocardiographic Assessment of Cardiac Structure and Function of Centenarians: A Systematic Review
by: Andrea Sonaglioni, et al.
Published: (2025-02-01)

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction
by: L. Healy, et al.
Published: (2025-04-01)

Incidence and risk factors of heart failure with preserved ejection fraction in elderly patients with hypertension
by: Min Chen, et al.
Published: (2024-12-01)

Identification of noval diagnostic biomarker for HFpEF based on proteomics and machine learning
by: Muyashaer Abudurexiti, et al.
Published: (2025-04-01)

Variation in clinical and patient‐reported outcomes among complex heart failure with preserved ejection fraction phenotypes
by: Kelsey M. Flint, et al.
Published: (2020-06-01)